CTRI Number |
CTRI/2017/10/010115 [Registered on: 16/10/2017] Trial Registered Retrospectively |
Last Modified On: |
21/09/2021 |
Post Graduate Thesis |
No |
Type of Trial |
Observational |
Type of Study
|
Imaging |
Study Design |
Non-randomized, Active Controlled Trial |
Public Title of Study
|
A Safe and Non-invasive Breast Cancer Screening Solution |
Scientific Title of Study
|
Multicentric Study to evaluate the effectiveness of Thermalytix© (automated thermographic screening algorithms developed by NIRAMAI) as compared to standard screening modalities in subjects who show possible symptoms of suspected breast cancer |
Trial Acronym |
SANT17 |
Secondary IDs if Any
|
Secondary ID |
Identifier |
NI-THERMA-01 Version 1.1 Dated July 19th 2017 |
Protocol Number |
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
Name |
Dr Sudhakar S |
Designation |
Radiologist |
Affiliation |
HCG Cancer Hospital |
Address |
Department of Radiology
HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar
Bangalore KARNATAKA 560027 India |
Phone |
9008801379 |
Fax |
|
Email |
dr_sudhakar79@yahoo.com |
|
Details of Contact Person Scientific Query
|
Name |
Dr Sudhakar S |
Designation |
Radiologist |
Affiliation |
HCG Cancer Hospital |
Address |
Department of Radiology
HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar
Bangalore KARNATAKA 560027 India |
Phone |
9008801379 |
Fax |
|
Email |
dr_sudhakar79@yahoo.com |
|
Details of Contact Person Public Query
|
Name |
Geetha Manjunath |
Designation |
Chief Executive Officer |
Affiliation |
NIRAMAI Health Analytix Pvt Ltd |
Address |
A7-506, Elita Promenade,
J P Nagar 7th Phase
Bangalore KARNATAKA 560078 India |
Phone |
9880118379 |
Fax |
|
Email |
geetha@niramai.com |
|
Source of Monetary or Material Support
|
NIRAMAI Health Analytix Pvt Ltd, A7-506, Elita Promenade, JP Nagar 7th Phase, Bangalore - 560078 |
|
Primary Sponsor
|
Name |
NIRAMAI Health Analytix Pvt Ltd |
Address |
A7-506 Elita Promenade J P Nagar 7th Phase Bangalore
|
Type of Sponsor |
Other [HealthTech Company] |
|
Details of Secondary Sponsor
|
|
Countries of Recruitment
|
India |
Sites of Study
|
No of Sites = 2 |
Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
Dr S Sudhakar |
HCG Cancer Hospital |
HCG Towers No 8 Kalinga Rao Road Sampangi Ram Nagar
Bengaluru Karnataka 560027
Bangalore KARNATAKA |
08040206000
dr_sudhakar79@yahoo.com |
Dr Venkatraman Bhat |
Mazumdar Shaw Medical Center |
Mazumdar Shaw Medical Center Narayana Hrudayalaya Limited No 258/A Bommasandra Industrial Area Anekal Taluk Bengaluru 560 099 Bangalore KARNATAKA |
9481027387
venkatraman.bhat.dr@narayanahealth.org |
|
Details of Ethics Committee
|
No of Ethics Committees= 2 |
Name of Committee |
Approval Status |
HCGCEC |
Approved |
NHEC |
Approved |
|
Regulatory Clearance Status from DCGI
|
|
Health Condition / Problems Studied
Modification(s)
|
Health Type |
Condition |
Patients |
(1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site, (2) ICD-10 Condition: R688||Other general symptoms and signs, possible symptoms of suspected breast cancer
, |
|
Intervention / Comparator Agent
|
Type |
Name |
Details |
Comparator Agent |
Clinical Breast Examination, Sono-Mammography and
Mammography |
Clinical Breast Examination, Sono-Mammography and
Mammography are standard screening modalities for Breast cancer. |
|
Inclusion Criteria
|
Age From |
18.00 Year(s) |
Age To |
70.00 Year(s) |
Gender |
Female |
Details |
1. Female subjects equal to and above 18 years presenting with the following breast abnormalities:
(1a) Palpable lump, swelling or mass in breast
(1b) Persistent breast pain or tenderness that is unrelated to menstrual cycle
(1c) Nipple is inverted or tender, painful, scaly or with discharge (clear or bloody)
(1d) Skin on breast is dimpled, red, blotchy, pricking, itchy or has change in the texture
(1e) Increase in breast size that is not related to menstrual cycle
(1f) Thickening in or around the breast or underarm area
(1g) Or any other symptoms leading to suspicion of breast cancer
2. Subjects who are willing to give written informed consent for study participation
3. Subjects who are ready to comply with the study related visits and procedures
|
|
ExclusionCriteria |
Details |
1. Subjects who are pregnant
2. Subjects who are lactating
3. Subjects who have undergone either lumpectomy or mastectomy
4. Subjects who have undergone Chemotherapy in the last 2 weeks at the time of study enrollment
5. Any active illness, psychological and/or pathological condition that would interfere with study participation in the opinion of the Investigator
|
|
Method of Generating Random Sequence
|
Not Applicable |
Method of Concealment
|
Not Applicable |
Blinding/Masking
|
Not Applicable |
Primary Outcome
|
Outcome |
TimePoints |
1. non-inferiority of sensitivity of Thermalytix to not more than 10% of the standard screening modalities
2.Sensitivity
3. Specificity
4.PPV
5.NPV |
24 weeks |
|
Secondary Outcome
|
Outcome |
TimePoints |
1. Influence of patient characteristics on diagnostic accuracy of Thermalytix©.
Patient characteristics will include:
(a) Age
(b) Lesion type
(c) Pathologic diagnosis
(d) Menopausal and hormonal status
(e) Breast density
(f) Family history
(g) Risk factors
2. Recommend how Thermalytix© can be used to complement standard breast cancer screening procedure.
|
24 weeks |
|
Target Sample Size
|
Total Sample Size="275" Sample Size from India="275"
Final Enrollment numbers achieved (Total)= "258"
Final Enrollment numbers achieved (India)="258" |
Phase of Trial
|
N/A |
Date of First Enrollment (India)
|
21/09/2017 |
Date of Study Completion (India) |
31/07/2018 |
Date of First Enrollment (Global) |
21/09/2017 |
Date of Study Completion (Global) |
31/07/2018 |
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Completed |
Recruitment Status of Trial (India) |
Completed |
Publication Details
|
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
|
Brief Summary
Modification(s)
|
Breast cancer is one of the crucially prevailing cancers among women. Early detection and diagnosis of breast cancer is very important for patient survival. Currently, mammography is the most common method used for detection of breast cancer. However, mammography has certain limitations. It is not recommended to be used on women under the age of 45 years, cannot be used on lactating women and is inconclusive on women with high density of breast. Mammography in correlation with sono-mammography is widely used currently for screening in hospitals . Infrared imaging of the breast or thermography is an imaging technique which detects suspected malignancy based on thermal changes on the chest. Due to increased blood circulation and metabolic activity of the tumour, the temperature of the tissue is higher around the regions where a tumor is present. A high resolution thermal camera can be used to capture this thermal information. This thermal image representing the temperature variations observed on the breast is called a breast thermogram. A thermal image provides a visual representation of the temperature distribution and can be used for clinical interpretation of abnormal breast conditions as an adjunct modality. Particularly, radiologists who are also certified thermologists are able to interpret these breast thermograms to determine its malignancy or benign condition. However, manual interpretation of these themograms is very cumbersome and error prone. Thermalytix is a new method of interpreting thermal images using CAD anovel Artificial Intelligence and Machine Learning Algorithms and has shown promising results in early experiments. Our proposed research is to improve breast cancer screening through low cost, mobile, non-invasive and non-contact thermal screening without causing any discomfort to patients and develop accurate interpretation algorithms using machine learning, image processing and computer vision techniques to give automated screening capabilities. In this study, sensitivity of Thermalytix© (an automated thermographic screening algorithms developed by NIRAMAI) will be compared to the sensitivity of standard screening modalities. The entry criteria for the study will be subjects who show possible symptoms of suspected breast cancer, such as pain, lump and so on. The primary objectives of the study are to assess a non-inferiority of sensitivity of Thermalytix© methodology over the sensitivity of standard screening procedures by not more than 10% and study comparative diagnostic performance of Thermalytix© with standard screening modalities. The endpoint measurements would be sensitivity, specificity, PPV (Positive Predictive Values) and NPV (Negative Predictive Values) in the detection of breast cancer in women. Secondary Objectives would be to study the influence of effects of patient characteristics on diagnostic accuracy. Patient characteristics would include, Age, Lesion type, Pathologic diagnosis, Menopausal and hormonal status, Breast density and Family history. Also to study how Thermalytix© can complement the standard modalities in breast cancer screening in future This protocol for human research study will be conducted according to standards of effective Good Clinical Practice (International Conference on Harmonization (ICH) Guidelines), if applicable the Indian regulations and applicable Ethical Guidelines for Biomedical Research involving Human Participants issued by the Indian Council of Medical Research. The trial protocol and subject documentation will be reviewed and approved by the Institutional Ethical Review Boards of the participating trial sites. |